Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

This is an interventional treatment trial for Non Small Cell Lung Cancer focused on measuring Non Small Cell Lung Cancer, Wild Type EGFR, Icotinib, Second-line Treatment Read More

Inclusion Criteria:

• Histologically or cytologically confirmed stage IIIB/IV NSCLC patients progressing after first-line chemotherapy;
• Patients must have stopped prior platinum-based therapy at least four weeks prior to enroll and fully recovered from chemotherapy-induced toxicity;
• Age: 18-70 years old;
• Patients with wild-type EGFR;
• With a histologically or cytologically confirmed measurable disease (longest diameters >=10mm with Spiral computed tomography (CT)and >=20mm with conventional CT) according to Response Evaluation Criteria in Solid Tumors (RECIST Criteria);
• Patients must have Eastern Cooperative Oncology Group(ECOG)Performance Status of 0-2;
• Must have an expected survival time of at least 12 weeks;
• Patients should have adequate bone marrow function defined as an absolute peripheral neutrophil count (ANC) of ≥1.5 ´ 109/L, platelet count of ≥ 75´ 109/L; Hemoglobin(Hb) ≥ 9g/dL;
• adequate hepatic function: bilirubin ≤2x the upper limit of normal, glutamic-oxaloacetic transaminase(AST )and glutamate pyruvate transaminase(ALT)≤2x the upper limit of normal (≤5x the upper limit of normal if evidence of liver metastases);
• adequate renal function: bilirubin serum creatinine ≤1.5 x the upper limit of normal;
• No malabsorption or other gastrointestinal disorders affecting drug absorption;
• Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to study entry.Male patients must use at least one reliable form of contraception during treatment and within 3 months after treatment;
• Patients have provided a signed Informed Consent Form.

Exclusion Criteria:

• Experience of Anti-EGFR Monoclonal Antibody or small molecular compounds therapy such as gefitinib, cetuximab, erlotinib or trastuzumab;
• Concomitant use with phenytoin, carbamazepine, rifampicin, phenobarbital or St. John's Wort;
• Allergic to icotinib or any of the excipients of this product.
• Prior chemotherapy with any paclitaxel agents;
• Central nervous system (CNS) metastases without radiotherapy and/or surgery;
• Evidence of clinically active Interstitial lung diseases;
• Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases;
• Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non melanoma skin cancer or cervical carcinoma in situ);
• Psychiatric illness that would prevent the patient from giving informed consent;
• Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study;
• Patient is concurrently using other approved or investigational antineoplastic agent;
• Pregnant or lactating women;
• Positive epidermal growth factor receptor mutation.